Q-omics provides the consensus-scored PRKAA1 profile across patient tissues and cancer cell-line models. PRKAA1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRKAA1 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, PRKAA1 protein abundance shows 20,517 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, THCA, and GBM as cancer lineages where PRKAA1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKAA1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKAA1 survival associations across molecular data types. PRKAA1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKAA1 RNA expression–survival associations across cancer types. High PRKAA1 expression shows unfavorable associations in LGG, CESC, UVM and MESO, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRKAA1 RNA expression.
This table summarizes PRKAA1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for PRKAA1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKAA1 shows lower tumor expression in THCA, BRCA and UCEC and higher tumor expression in HNSC, LUAD and STAD. The THCA box plot shows higher PRKAA1 RNA expression in normal versus tumor tissue (log2 FC = −0.721, t-test p < 0.001).
This table shows molecular features associated with PRKAA1 in patient tissues and cancer cell lines. In patient samples, PRKAA1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKAA1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
